On June 15, Insilico Medicine rose 5.61% in regular trading, trading at 36.36 HKD/share, with turnover of 31.75 million HKD.

On the news front, the company was formally included in the CSI Index series effective the same day, covering the CSI Hong Kong Stock Connect Innovative Drug Index, CSI Hong Kong Innovative Drug Index, and CSI Hong Kong Stock Connect Healthcare Composite Index. Additionally, the company is set to be included in the FTSE Global Equity Index Series on June 22, covering the FTSE Global Small Cap Index, FTSE Global All Cap Index, and FTSE Global Total Cap Index. The dual index inclusion is expected to attract passive fund inflows tracking these indices, enhance trading liquidity, and diversify the shareholder base, significantly improving short-term market sentiment.

However, approximately 453 million restricted shares held by cornerstone investors and employees will see their lock-up period expire on June 29, representing 81.25% of total share capital. Potential concentrated selling pressure remains a key concern going forward.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)